Spotlight on Surgery

Credits: 0.5 CME
An Integrated Approach to Chronic Active AMR in Renal Transplantation: Tying Together Pathogenesis, Diagnosis, and Emerging Treatment — Deciphering the Root Cause of Chronic Active Antibody-Mediated Rejection in Renal Transplant
Stanley C. Jordan, MD, FASN, FAST
RMEI Medical Education, LLC

An Integrated Approach to Chronic Active AMR in Renal Transplantation: Tying Together Pathogenesis, Diagnosis, and Emerging Treatment — Deciphering the Root Cause of Chronic Active Antibody-Mediated Rejection in Renal Transplant

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: June 7, 2022
Expires: June 6, 2023
30 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for transplant, nephrology, general surgery, and internal medicine clinicians involved in care of patients with antibody-mediated rejection (AMR).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Examine the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients
  • Employ established criteria to diagnose kidney transplant recipients with chronic active AMR

Activity Description

This learner-friendly, 30-minute infographic activity is augmented by expert and patient videos with an interactive approach to examining the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody mediated-rejection (AMR) in kidney transplant recipients. Important highlights include risk factors and diagnostic criteria for chronic active AMR.

Faculty

Stanley C. Jordan, MD, FASN, FAST
Director, Nephrology & Transplant Immunology
Medical Director, Kidney Transplant Program
Cedars-Sinai Medical Center
Los Angeles, CA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Stanley C. Jordan, MD, FASN, FAST, has relevant financial relationships with Argenx, CareDx, CSL Behring, Hansa, Regeneron, Vera (Consultant); CSL Behring, Hansa, One Legacy (Grant/Research Support).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent educational grant from CSL Behring LLC.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: June 7, 2022
Expires: June 6, 2023
30 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for transplant, nephrology, general surgery, and internal medicine clinicians involved in care of patients with antibody-mediated rejection (AMR).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Examine the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients
  • Employ established criteria to diagnose kidney transplant recipients with chronic active AMR

Activity Description

This learner-friendly, 30-minute infographic activity is augmented by expert and patient videos with an interactive approach to examining the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody mediated-rejection (AMR) in kidney transplant recipients. Important highlights include risk factors and diagnostic criteria for chronic active AMR.

Faculty

Stanley C. Jordan, MD, FASN, FAST
Director, Nephrology & Transplant Immunology
Medical Director, Kidney Transplant Program
Cedars-Sinai Medical Center
Los Angeles, CA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Stanley C. Jordan, MD, FASN, FAST, has relevant financial relationships with Argenx, CareDx, CSL Behring, Hansa, Regeneron, Vera (Consultant); CSL Behring, Hansa, One Legacy (Grant/Research Support).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent educational grant from CSL Behring LLC.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Surgery Presentations

0.75 CME
RMEI Medical Education, LLC
Antibody-Mediated Rejection in Renal Transplantation: Immune Mechanisms, Diagnostic Criteria, & Therapeutic Advances: A Clinical Olympics℠

Antibody-Mediated Rejection in Renal Transplantation: Immune Mechanisms, Diagnostic Criteria, & Therapeutic Advances: A Clinical Olympics℠

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: August 10, 2022
Expires: August 9, 2023
45 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for transplant, nephrology, general surgery, and internal medicine clinicians managing transplant patients with antibody-mediated rejection (AMR).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify the pathophysiology of chronic active antibody-mediated rejection (AMR) that leads to deleterious clinical manifestations in kidney transplant patients
  • Apply Banff diagnostic criteria for chronic active AMR in renal allografts
  • Examine the potential role of emerging therapeutic approaches in the management of chronic active AMR

Activity Description

Although over 100,000 renal transplants are performed worldwide each year, only a fraction of recipients are living with functioning renal grafts. Approximately 40% of renal transplants fail within 10 years. Chronic, or late, renal graft rejection is a leading cause of failure. Management of chronic active antibody-mediated rejection (AMR) is a major challenge due to the lack of both approved treatment options and clinical evidence informing current guidelines. In this fast-paced, highly interactive activity, Drs. Jordan, Djamali, and Schinstock will take you through the pathophysiology, diagnosis, and emerging therapeutics for chronic active AMR.

Chair

Stanley C. Jordan, MD, FASN, FAST
Director, Nephrology & Transplant Immunology
Medical Director, Kidney Transplant Program
Cedars-Sinai Medical Center
Los Angeles, CA

Faculty

Arjang Djamali, MD
Chair, Department of Medicine
Maine Medical Center
Portland, ME


Carrie A. Schinstock, MD
Associate Professor
Division of Nephrology and Hypertension
Mayo Clinic
Rochester, MN

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.   

Faculty

Arjang Djamali, MD, has relevant financial relationships with CareDX, CSL Behring (Advisor).

Stanley C. Jordan, MD, FASN, FAST, has relevant financial relationships with Argenx, CareDx, CSL Behring, Hansa, Regeneron, Vera (Consultant); CSL Behring, Hansa, One Legacy (Grant/Research Support).

Carrie A. Schinstock, MD, has relevant financial relationships with Alexion Pharmaceuticals, CSL Behring, Genentech, Sanofi (Researcher); CSL Behring (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent educational grant from CSL Behring LLC.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: August 10, 2022
Expires: August 9, 2023
45 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for transplant, nephrology, general surgery, and internal medicine clinicians managing transplant patients with antibody-mediated rejection (AMR).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify the pathophysiology of chronic active antibody-mediated rejection (AMR) that leads to deleterious clinical manifestations in kidney transplant patients
  • Apply Banff diagnostic criteria for chronic active AMR in renal allografts
  • Examine the potential role of emerging therapeutic approaches in the management of chronic active AMR

Activity Description

Although over 100,000 renal transplants are performed worldwide each year, only a fraction of recipients are living with functioning renal grafts. Approximately 40% of renal transplants fail within 10 years. Chronic, or late, renal graft rejection is a leading cause of failure. Management of chronic active antibody-mediated rejection (AMR) is a major challenge due to the lack of both approved treatment options and clinical evidence informing current guidelines. In this fast-paced, highly interactive activity, Drs. Jordan, Djamali, and Schinstock will take you through the pathophysiology, diagnosis, and emerging therapeutics for chronic active AMR.

Chair

Stanley C. Jordan, MD, FASN, FAST
Director, Nephrology & Transplant Immunology
Medical Director, Kidney Transplant Program
Cedars-Sinai Medical Center
Los Angeles, CA

Faculty

Arjang Djamali, MD
Chair, Department of Medicine
Maine Medical Center
Portland, ME


Carrie A. Schinstock, MD
Associate Professor
Division of Nephrology and Hypertension
Mayo Clinic
Rochester, MN

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.   

Faculty

Arjang Djamali, MD, has relevant financial relationships with CareDX, CSL Behring (Advisor).

Stanley C. Jordan, MD, FASN, FAST, has relevant financial relationships with Argenx, CareDx, CSL Behring, Hansa, Regeneron, Vera (Consultant); CSL Behring, Hansa, One Legacy (Grant/Research Support).

Carrie A. Schinstock, MD, has relevant financial relationships with Alexion Pharmaceuticals, CSL Behring, Genentech, Sanofi (Researcher); CSL Behring (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent educational grant from CSL Behring LLC.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

0.5 CME
RMEI Medical Education, LLC
An Integrated Approach to Chronic Active AMR in Renal Transplantation: Tying Together Pathogenesis, Diagnosis, and Emerging Treatment — Deciphering the Root Cause of Chronic Active Antibody-Mediated Rejection in Renal Transplant

An Integrated Approach to Chronic Active AMR in Renal Transplantation: Tying Together Pathogenesis, Diagnosis, and Emerging Treatment — Deciphering the Root Cause of Chronic Active Antibody-Mediated Rejection in Renal Transplant

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: June 7, 2022
Expires: June 6, 2023
30 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for transplant, nephrology, general surgery, and internal medicine clinicians involved in care of patients with antibody-mediated rejection (AMR).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Examine the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients
  • Employ established criteria to diagnose kidney transplant recipients with chronic active AMR

Activity Description

This learner-friendly, 30-minute infographic activity is augmented by expert and patient videos with an interactive approach to examining the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody mediated-rejection (AMR) in kidney transplant recipients. Important highlights include risk factors and diagnostic criteria for chronic active AMR.

Faculty

Stanley C. Jordan, MD, FASN, FAST
Director, Nephrology & Transplant Immunology
Medical Director, Kidney Transplant Program
Cedars-Sinai Medical Center
Los Angeles, CA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Stanley C. Jordan, MD, FASN, FAST, has relevant financial relationships with Argenx, CareDx, CSL Behring, Hansa, Regeneron, Vera (Consultant); CSL Behring, Hansa, One Legacy (Grant/Research Support).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent educational grant from CSL Behring LLC.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: June 7, 2022
Expires: June 6, 2023
30 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for transplant, nephrology, general surgery, and internal medicine clinicians involved in care of patients with antibody-mediated rejection (AMR).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Examine the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients
  • Employ established criteria to diagnose kidney transplant recipients with chronic active AMR

Activity Description

This learner-friendly, 30-minute infographic activity is augmented by expert and patient videos with an interactive approach to examining the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody mediated-rejection (AMR) in kidney transplant recipients. Important highlights include risk factors and diagnostic criteria for chronic active AMR.

Faculty

Stanley C. Jordan, MD, FASN, FAST
Director, Nephrology & Transplant Immunology
Medical Director, Kidney Transplant Program
Cedars-Sinai Medical Center
Los Angeles, CA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Stanley C. Jordan, MD, FASN, FAST, has relevant financial relationships with Argenx, CareDx, CSL Behring, Hansa, Regeneron, Vera (Consultant); CSL Behring, Hansa, One Legacy (Grant/Research Support).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent educational grant from CSL Behring LLC.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fernanda P. Silveira, MD, MS, FIDSA, FAST
0.75 CME / MOC
RMEI Medical Education, LLC
CMV Perils in Transplant Recipients: Prevention, Resistance, and Safety Considerations – A Care Team Forum℠

CMV Perils in Transplant Recipients: Prevention, Resistance, and Safety Considerations – A Care Team Forum℠

Start

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: November 9, 2021
Expires: November 8, 2022
45 minutes to complete

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Target Audience

This activity is intended for infectious disease specialists (MD/DO/NP/PA) and other clinicians who manage solid organ or hematopoietic cell transplant patients with cytomegalovirus (CMV).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Recognize the importance of early cytomegalovirus (CMV) prophylaxis in hematopoietic stem cell transplant patients
  • Identify risk factors and emerging therapies for resistant CMV disease in solid organ transplant and hematopoietic stem cell transplant patients
  • Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities

Activity Description

In this activity, Drs. Kotton, Chemaly, and Silveira share insights on cytomegalovirus (CMV) prevention and emerging treatments for resistant and refractory CMV disease. Learn tips for avoiding and managing side effects of antiviral therapies. Hear first-hand from a transplant patient who shares his difficult journey with resistant CMV disease.

Statement of Educational Need

Although hematopoietic cell transplantation (HCT) and solid organ transplantation (SOT) are essential and often lifesaving, they are associated with potentially life-threatening opportunistic infections. Specifically, cytomegalovirus (CMV) infection is one of the most common infectious complications in patients undergoing HCT and SOT. Greater than 50% of solid organ transplant recipients may display evidence of CMV replication, and 10% to 50% may progress to symptomatic disease. CMV increases mortality risk and may cause organ damage even in the absence of obvious CMV disease. Current CMV antiviral treatments are limited by significant hematologic and renal toxicities, as well as resistance. Strategies to overcome these limitations, including novel antiviral therapies, vaccines, and T-cell therapies, offer hope for transplant patients who face the serious threat of CMV.

Faculty

Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA


Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ
Professor of Medicine
Department of ID/IC/EH
Chief Infection Control Officer
Director, Clinical Virology Research
UT MD Anderson Cancer Center
Houston, TX


Fernanda P. Silveira, MD, MS, FIDSA, FAST
Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Camille Nelson Kotton, MD, FIDSA, FAST, has affiliations with Merck (Adjudication Committee Member); Evrys, Hookipa, Merck, Oxford Immunotec, Shire/Takeda, Synklino (Consulting Fees); AiCuris, Hookipa, Oxford Immunotec (Contracted Research); Hookipa (Principal Investigator); Merck, Oxford Immunotec, Shire/Takeda (Speaker Bureau).

Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ, has affiliations with ADMA Biologics, Adagio, Ansun, Genentech, Janssen, Merck, Molecular Partners, Oxford Immunotec, Takeda (Consulting Fees); AiCuris, Ansun, Genentech, Janssen, Karius, Merck, Oxford Immunotec, Takeda, Viracor (Contracted Research).

Fernanda P. Silveira, MD, MS, FIDSA, FAST, has affiliations with Takeda (Consulting Fees); Ansun, Gilead, Novartis, Qiagen, Shire, SlieaGen (Contracted Research).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

Planners and Managers
The PIM planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity.

During the period from November 9, 2021 through November 8, 2022, participants must 1) read the learning objectives and disclosures; 2) study the educational activity; and 3) complete the post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC. 
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card. 

Statement of Commercial Support

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

If you have questions regarding the certification of this activity, please contact PIM via e-mail at inquiries@pimed.com.

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: November 9, 2021
Expires: November 8, 2022
45 minutes to complete

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Target Audience

This activity is intended for infectious disease specialists (MD/DO/NP/PA) and other clinicians who manage solid organ or hematopoietic cell transplant patients with cytomegalovirus (CMV).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Recognize the importance of early cytomegalovirus (CMV) prophylaxis in hematopoietic stem cell transplant patients
  • Identify risk factors and emerging therapies for resistant CMV disease in solid organ transplant and hematopoietic stem cell transplant patients
  • Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities

Activity Description

In this activity, Drs. Kotton, Chemaly, and Silveira share insights on cytomegalovirus (CMV) prevention and emerging treatments for resistant and refractory CMV disease. Learn tips for avoiding and managing side effects of antiviral therapies. Hear first-hand from a transplant patient who shares his difficult journey with resistant CMV disease.

Statement of Educational Need

Although hematopoietic cell transplantation (HCT) and solid organ transplantation (SOT) are essential and often lifesaving, they are associated with potentially life-threatening opportunistic infections. Specifically, cytomegalovirus (CMV) infection is one of the most common infectious complications in patients undergoing HCT and SOT. Greater than 50% of solid organ transplant recipients may display evidence of CMV replication, and 10% to 50% may progress to symptomatic disease. CMV increases mortality risk and may cause organ damage even in the absence of obvious CMV disease. Current CMV antiviral treatments are limited by significant hematologic and renal toxicities, as well as resistance. Strategies to overcome these limitations, including novel antiviral therapies, vaccines, and T-cell therapies, offer hope for transplant patients who face the serious threat of CMV.

Faculty

Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA


Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ
Professor of Medicine
Department of ID/IC/EH
Chief Infection Control Officer
Director, Clinical Virology Research
UT MD Anderson Cancer Center
Houston, TX


Fernanda P. Silveira, MD, MS, FIDSA, FAST
Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Camille Nelson Kotton, MD, FIDSA, FAST, has affiliations with Merck (Adjudication Committee Member); Evrys, Hookipa, Merck, Oxford Immunotec, Shire/Takeda, Synklino (Consulting Fees); AiCuris, Hookipa, Oxford Immunotec (Contracted Research); Hookipa (Principal Investigator); Merck, Oxford Immunotec, Shire/Takeda (Speaker Bureau).

Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ, has affiliations with ADMA Biologics, Adagio, Ansun, Genentech, Janssen, Merck, Molecular Partners, Oxford Immunotec, Takeda (Consulting Fees); AiCuris, Ansun, Genentech, Janssen, Karius, Merck, Oxford Immunotec, Takeda, Viracor (Contracted Research).

Fernanda P. Silveira, MD, MS, FIDSA, FAST, has affiliations with Takeda (Consulting Fees); Ansun, Gilead, Novartis, Qiagen, Shire, SlieaGen (Contracted Research).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

Planners and Managers
The PIM planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity.

During the period from November 9, 2021 through November 8, 2022, participants must 1) read the learning objectives and disclosures; 2) study the educational activity; and 3) complete the post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC. 
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card. 

Statement of Commercial Support

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

If you have questions regarding the certification of this activity, please contact PIM via e-mail at inquiries@pimed.com.

Roy S. Herbst, MD, PhD
0.75 CME / MOC
RMEI Medical Education, LLC
On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC: A Care Team Forum℠

On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC: A Care Team Forum℠

Start

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: October 29, 2021
Expires: October 28, 2022
45 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, pathologists, pulmonologists, and other clinicians engaged in the care of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Use biomarker testing to inform frontline treatment decisions in patients with advanced non-small cell lung cancer (NSCLC)
  • Assess current data on immune checkpoint inhibitors for the frontline treatment of advanced NSCLC 
  • Identify patients with advanced NSCLC in whom frontline treatment with an immune checkpoint inhibitor may be beneficial 
  • Recognize potential immunotherapy-related adverse events in patients with advanced NSCLC who are undergoing treatment with an immune checkpoint inhibitor in the frontline setting 

Activity Description

Immunotherapy has rapidly changed the landscape of therapeutic options for patients with metastatic NSCLC. Led by an expert panel, this activity will equip clinicians with the tools to identify patients eligible for frontline checkpoint inhibitor monotherapy. It will provide privileged insights into optimal therapeutic selection based on the latest clinical trial data and strategies for optimal management of adverse events. A patient panelist shares his treatment journey, offering a novel perspective for healthcare professionals.

Faculty

Roy S. Herbst, MD, PhD
Ensign Professor, Medicine (Medical Oncology) and Professor, Pharmacology 
Chief, Medical Oncology 
Yale Cancer Center and Smilow Cancer Hospital 
Associate Cancer Center Director, Translational Research  
Yale Cancer Center 
New Haven, CT 


Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology) 
Yale Cancer Center  
New Haven, CT


Prof. Aleš Ryška, MD, PhD
Head, Fingerland Department of Pathology  
Charles University, Medical Faculty  
Hradec Králové, Czech Republic

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Roy S. Herbst, MD, PhD, has financial relationships with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Inc., Checkpoint Therapeutics, Cybrexa Therapeutics, DynamiCure Biotechnology, LLC, eFFECTOR Therapeutics, Inc., Eli Lilly and Company, EMD Serono, Foundation Medicine, Inc., Genentech/Roche, Genmab, Gilead, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Johnson and Johnson, Loxo Oncology, Merck & Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Ocean Biomedical, Inc., Oncternal Therapeutics, Pfizer, Refactor Health, Inc., Ribbon Therapeutics, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Inc., Symphogen, Takeda, Tesaro, Tocagen, Ventana Medical Systems, Inc., WindMIL Therapeutics, Xencor, Inc. (Consultant); AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck & Company (Researcher); Immunocore Holdings Limited, Junshi Pharmaceuticals (Other: Board Member).

Sarah B. Goldberg, MD, MPH, has financial relationships with AstraZeneca, Boehringer Ingelheim, Blueprint Medicine, Bristol Myers Squibb, Daiichi-Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consultant); AstraZeneca, Boehringer Ingelheim (Researcher).

Prof. Aleš Ryška, MD, PhD, has financial relationships with Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Merck & Company, Roche (Advisor); Amgen, AstraZeneca, Merck & Company, Roche (Speaker’s Bureau).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: October 29, 2021
Expires: October 28, 2022
45 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, pathologists, pulmonologists, and other clinicians engaged in the care of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Use biomarker testing to inform frontline treatment decisions in patients with advanced non-small cell lung cancer (NSCLC)
  • Assess current data on immune checkpoint inhibitors for the frontline treatment of advanced NSCLC 
  • Identify patients with advanced NSCLC in whom frontline treatment with an immune checkpoint inhibitor may be beneficial 
  • Recognize potential immunotherapy-related adverse events in patients with advanced NSCLC who are undergoing treatment with an immune checkpoint inhibitor in the frontline setting 

Activity Description

Immunotherapy has rapidly changed the landscape of therapeutic options for patients with metastatic NSCLC. Led by an expert panel, this activity will equip clinicians with the tools to identify patients eligible for frontline checkpoint inhibitor monotherapy. It will provide privileged insights into optimal therapeutic selection based on the latest clinical trial data and strategies for optimal management of adverse events. A patient panelist shares his treatment journey, offering a novel perspective for healthcare professionals.

Faculty

Roy S. Herbst, MD, PhD
Ensign Professor, Medicine (Medical Oncology) and Professor, Pharmacology 
Chief, Medical Oncology 
Yale Cancer Center and Smilow Cancer Hospital 
Associate Cancer Center Director, Translational Research  
Yale Cancer Center 
New Haven, CT 


Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology) 
Yale Cancer Center  
New Haven, CT


Prof. Aleš Ryška, MD, PhD
Head, Fingerland Department of Pathology  
Charles University, Medical Faculty  
Hradec Králové, Czech Republic

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Roy S. Herbst, MD, PhD, has financial relationships with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Inc., Checkpoint Therapeutics, Cybrexa Therapeutics, DynamiCure Biotechnology, LLC, eFFECTOR Therapeutics, Inc., Eli Lilly and Company, EMD Serono, Foundation Medicine, Inc., Genentech/Roche, Genmab, Gilead, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Johnson and Johnson, Loxo Oncology, Merck & Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Ocean Biomedical, Inc., Oncternal Therapeutics, Pfizer, Refactor Health, Inc., Ribbon Therapeutics, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Inc., Symphogen, Takeda, Tesaro, Tocagen, Ventana Medical Systems, Inc., WindMIL Therapeutics, Xencor, Inc. (Consultant); AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck & Company (Researcher); Immunocore Holdings Limited, Junshi Pharmaceuticals (Other: Board Member).

Sarah B. Goldberg, MD, MPH, has financial relationships with AstraZeneca, Boehringer Ingelheim, Blueprint Medicine, Bristol Myers Squibb, Daiichi-Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consultant); AstraZeneca, Boehringer Ingelheim (Researcher).

Prof. Aleš Ryška, MD, PhD, has financial relationships with Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Merck & Company, Roche (Advisor); Amgen, AstraZeneca, Merck & Company, Roche (Speaker’s Bureau).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.